期刊文献+

人尿中对乙酰氨基苯甲酸和N,N-二甲氨基-2-丙醇的液质联用法测定及尿药排泄特征研究 被引量:7

Determination of p-Acetaminobenzoic Acid and N,N-Dimethylamino-2-propanol in Human Urine by LC-MS and Study on Their Urinary Excretion Profiles
原文传递
导出
摘要 目的:建立分别测定人尿中对乙酰氨基苯甲酸和N,N-二甲氨基-2-丙醇的液质联用法,考察二者在中国健康受试者尿液中的排泄特征。方法:以LC-MS法测定尿样中对乙酰氨基苯甲酸,色谱采用Amethyst C18柱(150 mm×2.1 mm,5μm),流动相为甲醇-0.1%甲酸水溶液(25∶75),流速为0.4 mL.min-1;质谱采用气动辅助电喷雾离子化和正离子选择性离子检测。以LC-MS/MS法测定尿样中N,N-二甲氨基-2-丙醇,色谱采用Hedera CN柱(150 mm×2.1 mm,5μm),流动相为乙腈-5 mmol.L-1醋酸铵水溶液(含0.03%甲酸)(55∶45),流速为0.35 mL.min-1;质谱采用气动辅助电喷雾离子化和正离子多反应检测。10名受试者单次口服异丙肌苷片(1.0 g),测定对乙酰氨基苯甲酸和N,N-二甲氨基-2-丙醇的尿药排泄参数。结果:对乙酰氨基苯甲酸的尿药浓度在0.202 0~202.0 mg.L-1范围内线性关系良好,平均回收率大于97.7%;N,N-二甲氨基-2-丙醇尿药浓度在0.797 8~398.9 mg.L-1范围内线性关系良好,平均回收率大于99.1%。受试者服药后,对乙酰氨基苯甲酸和N,N-二甲氨基-2-丙醇分别在6和12 h后基本随尿排泄完全,36 h内其平均尿药累积排泄百分率分别为(30.7±5.7)%和(49.0±8.6)%。结论:本法适用于人尿中对乙酰氨基苯甲酸和N,N-二甲氨基-2-丙醇的测定及其尿药排泄特征研究。 Objective: To establish LC-MS methods for the separate determination of p-acetaminobenzoic acid(PAcBA) and N,N-dimethylamino-2-propanol(DIP) in human urine,and to investigate their urinary excretion profiles in Chinese healthy volunteers.Methods:PAcBA in urine was determined by LC-MS using Amethyst C18-P column,with methanol-0.1% formic acid(25 ∶75) as mobile phase at a flow rate of 0.4 mL ·min-1 and positive ion SIM detection;DIP in urine was determined by LC-MS/MS using Hedera CN column,with acetonitrile-5 mmol ·L-1 ammonium acetate(55 ∶45) containing 0.03% formic acid as mobile phase at a flow rate of 0.35 mL ·min-1 and positive ion MRM detection.The urinary excretion parameters of PAcBA and DIP were measured after a single oral administration of isoprinosine tablets(1.0 g) in 10 volunteers.Results: The calibration curve was linear in the range of 0.202 0-202.0 mg ·L-1 for PAcBA in urine or in the range of 0.797 8-398.9 mg ·L-1 for DIP in urine.The average recoveries of PAcBA and DIP in urine were more than 97.7% and 99.1%,respectively.After taking the tablets,PAcBA and DIP were almost completely excreted in urine and the average cumulative excretion percentages of PAcBA and DIP in urine within 36 h were(30.7±5.7)% and(49.0±8.6)%,respectively.Conclusion:The methods are suitable for the determination of PAcBA and DIP in human urine and for the investigation on their urinary excretion profiles.
出处 《药学进展》 CAS 2011年第9期417-423,共7页 Progress in Pharmaceutical Sciences
关键词 含量测定 液质联用 尿药排泄 异丙肌苷 对乙酰氨基苯甲酸 N N-二甲氨基-2-丙醇 quantitative analysis LC-MS urinary drug excretion isoprinosine p-acetamidobenzoic acid N N-dimethylamino-2-propanol
  • 相关文献

参考文献8

二级参考文献6

共引文献20

同被引文献80

  • 1郑家润.皮肤局部用药的安全性评价[J].中国新药杂志,2005,14(3):257-259. 被引量:8
  • 2王沈阳,丁黎,郝歆愚,李丽敏.替加色罗大鼠血浆蛋白的结合率测定[J].江苏药学与临床研究,2006,14(1):10-11. 被引量:3
  • 3Jun Haeng Lee,Jae J Kim,Ki-Baik Hahm,Dong Ho Lee,Nayoung Kim,Sung Kook Kim,Jong Jae Park,Seok Reyol Choi,Jong Hun Lee,Soo Teik Lee,Eun Hyun Lee,Jong Chul Rhee.Efficacy and safety of ecabet sodium on functional dyspepsia:A prospective,double-blinded,randomized,multi-center controlled trial[J].World Journal of Gastroenterology,2006,12(17):2756-2761. 被引量:3
  • 4濮智颖,翟文俊,杨春霞,徐青梅,李白存.全发酵石榴酒的营养价值和保健作用[J].食品科技,2007,32(8):278-281. 被引量:12
  • 5FUJIWARA Y, YAMAMOTO N, YAMADA Y, et ol. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydrox- amie acid) in Japanese patients with solid tumors[J]. Cancer Sci, 2009, 100(9): 1728-1734.
  • 6MARKS PA, BRESLOW R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an antieancer drug[Jl. Nat Biotechnol, 2007, 25 (1) : 84-90.
  • 7KELLY WK, O'CONNOR OA, KRUG LM, et al. Phase I study of an oral histone deaeetylase inhibitor, suberoylanilide hydrox- amic acid, in patients with advanced cancer[J]. J Clin Oneol, 2005, 23(17) : 3923-3931.
  • 8DU L, MUSSON DG,WANG AQ. High turbulence liquid chroma- tography online extraetion and tandem mass speetrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum[J]. Rapid Commun Mass Speetrom, 2005, 19(13): 1779-1787.
  • 9PARISE RA, HOLLERAN JL, BEUMER JH, et al. A liquid ehromatography-eleetrospray ionization tandem mass spectro- metric assay for quantitation of the histone deaeetylase inhibitor, vorinostat ( suberoylanilide hydroxamieaeid, SAHA ) , and its metabolites in human serum[J]. J Chromatogr B, 2006, 840(2): 108-115.
  • 10RUB1N EH, AGRAWAL NG, FRIEDMAN E J, et d. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer[J]. Clin Cancer Res, 2006, 12(23): 7039-7045.

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部